BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10842197)

  • 21. Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following "suicide" gene therapy in a murine colon carcinoma model.
    Alsheikhly AR; Zweiri J; Walmesley AJ; Watson AJ; Christmas SE
    Cancer Immunol Immunother; 2004 Nov; 53(11):946-54. PubMed ID: 15185012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
    Furumoto K; Soares L; Engleman EG; Merad M
    J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells.
    Chaudhry UI; Katz SC; Kingham TP; Pillarisetty VG; Raab JR; Shah AB; DeMatteo RP
    FASEB J; 2006 May; 20(7):982-4. PubMed ID: 16571772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus.
    Morelli AE; Antonysamy MA; Takayama T; Hackstein H; Chen Z; Qian S; Zurowski NB; Thomson AW
    J Immunol; 2000 Jul; 165(1):226-37. PubMed ID: 10861056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo.
    Karsunky H; Merad M; Cozzio A; Weissman IL; Manz MG
    J Exp Med; 2003 Jul; 198(2):305-13. PubMed ID: 12874263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Flt-3-ligand-mobilized dendritic cells require additional activation to drive effective immune responses.
    Diener KR; Moldenhauer LM; Lyons AB; Brown MP; Hayball JD
    Exp Hematol; 2008 Jan; 36(1):51-60. PubMed ID: 17949888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer.
    Larmonier CB; Arnould L; Larmonier N; Baumann S; Moutet M; Saint-Giorgio V; Pance A; Jeannin JF
    Int J Mol Med; 2004 Mar; 13(3):355-61. PubMed ID: 14767564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].
    Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand, GM-CSF and Flt3 ligand plus GM-SCF.
    Daro E; Butz E; Smith J; Teepe M; Maliszewski CR; McKenna HJ
    Cytokine; 2002 Feb; 17(3):119-30. PubMed ID: 11895330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo generation of dendritic cells by intramuscular codelivery of FLT3 ligand and GM-CSF plasmids.
    Peretz Y; Zhou ZF; Halwani F; Prud'homme GJ
    Mol Ther; 2002 Sep; 6(3):407-14. PubMed ID: 12231178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
    Correale P; Botta C; Cusi MG; Del Vecchio MT; De Santi MM; Gori Savellini G; Bestoso E; Apollinari S; Mannucci S; Marra M; Abbruzzese A; Aquino A; Turriziani M; Bonmassar L; Caraglia M; Tagliaferri P
    Int J Cancer; 2012 Apr; 130(7):1577-89. PubMed ID: 21618510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model.
    Chen K; Braun S; Lyman S; Fan Y; Traycoff CM; Wiebke EA; Gaddy J; Sledge G; Broxmeyer HE; Cornetta K
    Cancer Res; 1997 Aug; 57(16):3511-6. PubMed ID: 9270021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
    Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
    Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rehmannia glutinosa polysaccharide induced an anti-cancer effect by activating natural killer cells.
    Xu L; Zhang W; Zeng L; Jin JO
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):680-685. PubMed ID: 28716751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ecklonia cava fucoidan has potential to stimulate natural killer cells in vivo.
    Zhang W; An EK; Park HB; Hwang J; Dhananjay Y; Kim SJ; Eom HY; Oda T; Kwak M; Lee PC; Jin JO
    Int J Biol Macromol; 2021 Aug; 185():111-121. PubMed ID: 34119543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.
    Solheim JC; Reber AJ; Ashour AE; Robinson S; Futakuchi M; Kurz SG; Hood K; Fields RR; Shafer LR; Cornell D; Sutjipto S; Zurawski S; LaFace DM; Singh RK; Talmadge JE
    Cancer Gene Ther; 2007 Apr; 14(4):364-71. PubMed ID: 17235356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma.
    Esche C; Subbotin VM; Maliszewski C; Lotze MT; Shurin MR
    Cancer Res; 1998 Feb; 58(3):380-3. PubMed ID: 9458075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.